Neurovalens has raised a total of $30.4 million to date, with plans to close a Series B round by the end of the year, potentially adding another $40 million to their coffers. While these figures may seem modest compared to the hundreds of millions raised by companies like Neuralink, they reflect the cost-efficiency of developing non-invasive technologies.
The market potential for neurotech is another factor driving investor interest. Current projections suggest that the overall neurotech market – including both invasive and non-invasive technologies – could grow from its current value of around $13-14 billion to $40 billion by 2030. This growth potential, combined with the lower barriers to entry for non-invasive technologies, makes it an appealing sector for investment.